SG Americas Securities LLC raised its stake in shares of Hologic (NASDAQ:HOLX) by 199.6% during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 54,341 shares of the medical equipment provider’s stock after purchasing an additional 36,201 shares during the quarter. SG Americas Securities LLC’s holdings in Hologic were worth $2,030,000 at the end of the most recent reporting period.
Several other large investors have also added to or reduced their stakes in the company. Creative Planning grew its position in shares of Hologic by 8.2% in the 4th quarter. Creative Planning now owns 15,396 shares of the medical equipment provider’s stock worth $658,000 after buying an additional 1,161 shares during the period. AT Bancorp grew its position in shares of Hologic by 2.2% in the 4th quarter. AT Bancorp now owns 62,329 shares of the medical equipment provider’s stock worth $2,664,000 after buying an additional 1,323 shares during the period. Flinton Capital Management LLC grew its position in shares of Hologic by 9.2% in the 4th quarter. Flinton Capital Management LLC now owns 18,904 shares of the medical equipment provider’s stock worth $808,000 after buying an additional 1,598 shares during the period. Greenleaf Trust grew its position in shares of Hologic by 1.5% in the 4th quarter. Greenleaf Trust now owns 112,101 shares of the medical equipment provider’s stock worth $4,792,000 after buying an additional 1,675 shares during the period. Finally, Public Employees Retirement Association of Colorado grew its position in shares of Hologic by 0.5% in the 4th quarter. Public Employees Retirement Association of Colorado now owns 368,144 shares of the medical equipment provider’s stock worth $15,738,000 after buying an additional 1,776 shares during the period. 98.47% of the stock is currently owned by hedge funds and other institutional investors.
Shares of HOLX stock opened at $38.70 on Thursday. Hologic has a one year low of $37.84 and a one year high of $38.15. The stock has a market cap of $10.34 billion, a P/E ratio of 18.21, a PEG ratio of 1.78 and a beta of 0.87. The company has a current ratio of 1.26, a quick ratio of 0.98 and a debt-to-equity ratio of 1.13.
Hologic (NASDAQ:HOLX) last announced its quarterly earnings data on Wednesday, May 2nd. The medical equipment provider reported $0.53 EPS for the quarter, meeting the Thomson Reuters’ consensus estimate of $0.53. Hologic had a negative net margin of 4.15% and a positive return on equity of 20.86%. The company had revenue of $789.30 million for the quarter, compared to the consensus estimate of $781.23 million. During the same period in the prior year, the firm posted $0.50 EPS. Hologic’s revenue for the quarter was up 10.3% on a year-over-year basis. analysts forecast that Hologic will post 2.24 EPS for the current year.
A number of research firms have recently weighed in on HOLX. Deutsche Bank downgraded shares of Hologic from a “buy” rating to a “hold” rating and set a $49.00 target price on the stock. in a research report on Friday, January 19th. BidaskClub downgraded shares of Hologic from a “sell” rating to a “strong sell” rating in a research report on Thursday, January 25th. Needham & Company LLC reaffirmed a “buy” rating and issued a $50.00 target price on shares of Hologic in a research report on Thursday, February 1st. Canaccord Genuity downgraded shares of Hologic from a “buy” rating to a “hold” rating and reduced their target price for the stock from $48.00 to $39.00 in a research report on Thursday, May 3rd. Finally, Stifel Nicolaus reduced their target price on shares of Hologic from $42.00 to $40.00 and set a “hold” rating on the stock in a research report on Thursday, May 3rd. Two equities research analysts have rated the stock with a sell rating, six have given a hold rating and nine have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and a consensus target price of $44.87.
In related news, SVP Allison P. Bebo sold 7,000 shares of the stock in a transaction dated Friday, March 16th. The shares were sold at an average price of $38.75, for a total transaction of $271,250.00. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Charles J. Dockendorff acquired 13,000 shares of the business’s stock in a transaction that occurred on Thursday, March 15th. The shares were purchased at an average cost of $38.80 per share, for a total transaction of $504,400.00. The disclosure for this purchase can be found here. Corporate insiders own 0.79% of the company’s stock.
Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women in the United States, Europe, the Asia-Pacific, and internationally. The company operates through five segments: Diagnostics, Breast Health, Medical Aesthetics, GYN Surgical, and Skeletal Health.
Receive News & Ratings for Hologic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic and related companies with MarketBeat.com's FREE daily email newsletter.